A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED June 26, 2020 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide updates as new… Read More »
VGXI Official Statement Regarding COVID-19
VGXI to Manufacture Vaccine Against Novel Coronavirus Under CEPI Funded Collaboration
Texas-based plasmid DNA Manufacturer VGXI, Inc. to Enable Accelerated Production of a Vaccine against the 2019 Novel Coronavirus in a CEPI Funded Collaboration The Woodlands, TX – VGXI, a world leading contract manufacturer of clinical grade DNA plasmid, announced it will start production of a DNA vaccine against the novel coronavirus (2019-nCoV) that has recently… Read More »
VGXI, Inc. Establishes Pilot mRNA Manufacturing Capabilities
Under a Technology License Agreement with the Houston Methodist Research Institute, Contract Developer and Manufacturer VGXI Achieves Key Milestones with Establishment of Pilot Production Capabilities for RNA-Based Medicines. The Woodlands, TX – VGXI announces successful implementation of new RNA production services through completion of all Phase II initiatives as part of a license agreement with… Read More »
VGXI Selects BE&K as Design-Build Partner for New Manufacturing Facility
Plasmid DNA Manufacturer VGXI, Inc. Selects BE&K Building Group as its Design-Build Partner for the Initial Phase of its New and Expanded Manufacturing Facility December 3, 2019, The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services company BE&K Building… Read More »
Texas Based CMO VGXI and Geneos Therapeutics Establish Supply Agreement for Production of GT-EPIC-Based Personalized Cancer Therapeutics
Industry recognized plasmid DNA manufacturer VGXI, Inc. to support production of personalized cancer therapies as part of a long-term supply agreement with Geneos Therapeutics. June 22, 2019, The Woodlands, TX and Plymouth Meeting, PA – Plasmid CMO VGXI, Inc. and Geneos Therapeutics, Inc., a spin-out of Inovio Pharmaceuticals (NASDAQ: INO) focused on developing DNA-based, Neoantigen-targeting personalized… Read More »
VGXI Announces Continued Progress for RNA Manufacturing Partnership
Texas based CMO VGXI Announces Completion of Initial Tech Transfer Milestones as part of its Partnership Agreement for Production of RNA Therapeutics with HMRI. March 15, 2019, The Woodlands, TX – Under a license agreement with the Houston Methodist Research Institute (HMRI) for development of clinical grade RNA manufacturing services, VGXI announced it has completed… Read More »
VGXI Celebrates Grand Opening of New Flex-Scale Production Plant for GMP
U.S. Congressman Kevin Brady visited Texas-based CMO VGXI to celebrate the grand opening of the company’s new flexible scale GMP production plant for DNA and RNA based therapeutics. VGXI, an industry recognized plasmid DNA contract manufacturing organization, announced the grand opening of a facility expansion which includes flexible scale plasmid DNA manufacturing space as well… Read More »
Meet VGXI at the AAV Gene Therapy Symposium
Meet with representatives from VGXI at the 2nd Annual AAV Gene Therapy Symposium on 10 December, 2018. We would welcome an opportunity to introduce ourselves and share information on VGXI’s customized plasmid DNA manufacturing solutions to support your AAV production needs. Contact Us today to request a meeting. 2018 AAV Gene Therapy Symposium 10 December, 2018 Bioscience… Read More »
VGXI Announces Exclusive License to Establish GMP-Grade RNA Manufacturing Services
Texas based CMO VGXI Announces Licensing Agreement with the Houston Methodist Research Institute for Production of RNA Therapeutics. The Woodlands, TX – September 17, 2018: VGXI, an industry leading plasmid DNA contract manufacturer, announced today that they have entered into an exclusive license with the Houston Methodist Research Institute to produce clinical grade RNA at… Read More »
GeneOne Announces Expansion into RNA Vaccines and Therapeutics
GeneOne Announces that its Subsidiary, Industry Leading Plasmid DNA CMO VGXI, has Entered into an Exclusive License to Produce RNA Biotherapeutics. Seoul, Korea – September 17, 2018: GeneOne Life Science announced today that its subsidiary VGXI, an industry leading plasmid DNA contract manufacturer, has entered into an exclusive license with the Houston Methodist Research Institute… Read More »
VGXI to Provide Plasmid Manufacturing under Client’s $56M CEPI Award
VGXI, a Texas-based cGMP plasmid CMO, will provide manufacturing support under client’s $56M CEPI award for the development of Lassa and MERS vaccines. The Woodlands, TX – April 30, 2018 – VGXI announced today they will collaborate with one of their clients on a recent $56,000,000 award from the Coalition for Epidemic Preparedness Innovations, or… Read More »
VGXI Promotes Dorothy Peterson to COO
GMP plasmid CMO VGXI appoints Dorothy Peterson as Chief Operating Officer, overseeing all aspects of the Texas-based production facility. The Woodlands, TX – April 25, 2018 – VGXI is pleased to announce that Vice President of Operations Dorothy Peterson has been appointed Chief Operating Officer. Peterson joined VGXI in 2007 as the Director of Quality… Read More »